Affinivax enters into research collaboration with ClearPath and Astellas on healthcare associated infections

26 October 2015

Biotech company Affinivax has entered into a collaboration agreement with Nosocomial Vaccine Corporation, which was established by ClearPath Development Company and its partner Astellas (TYO: 4503).

The collaborate will use Affinivax’s proprietary vaccine platform, called Multiple Antigen Presentation System, to develop vaccines that prevent bacterial nosocomial infections. These are also referred to as healthcare associated infections (HAIs). The funding from Nosocomial Vaccine is sufficient to support the development of product candidates to clinical testing.

HAIs are of significant global health concern and the USA’s Centers for Disease Control and Prevention estimate that 4% of patients in the country will contract an HAI every year in medical facilities. The cost of HAIs has been reported as $9.8 billion annually in the USA alone in JAMA Internal Medicine.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK